Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Lt.../ US8816242098 /
TEVA
2024. 05. 20. 21:59:55
|
Vált.
+0,52
|
Forgalom (db) |
Vétel- |
Eladás- |
Piaci kapitalizáció |
Osztalékh. |
P/E Ráta |
16,81USD
|
+3,16%
|
299 635 Forgalom: 5,01 mill. |
-Vétel (db): - |
-Eladás (db): - |
19,04 mrd.USD |
- |
- |
Cégbemutató
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies.
Igazgatóság & Felügyelőbizottság
CEO |
Kåre Schultz |
Igazgatóság |
Eli Kalif, David M. Stark, Dr. Hafrun Fridriksdottir, Eli Shani, Eric Drapé, Galia Inbar, Lori Queisser, Mark Sabag, Nir Baron, Richard Daniell, Sven Dethlefs |
Felügyelőbizottság |
Dr. Sol J. Barer, Amir Elstein, Dr. Perry D. Nisen, Dr. Tal Zaks, Gerald M. Lieberman, Janet S. Vergis, Jean-Michel Halfon, Kåre Schultz, Nechemia J. Peres, Prof. Ronit Satchi-Fainaro, Roberto A. Mignone, Rosemary A. Crane |
Cégadat
Név: |
Teva Pharmaceuticals Industries Ltd. |
Cím: |
5 Basel St.,Petach Tikva 49131, Israel |
Telefon: |
+972-3-914-8171 |
Fax: |
+972-3-914-8678 |
E-mail: |
-
|
Internet: |
www.tevapharm.com |
Ipar: |
Gyógyászat |
Szektor: |
Gyógyszeripar |
Alszektor: |
Gyógyszerek |
Pénzügyi év vége: |
12. 31. |
Közkézhányad: |
88,20% |
IPO dátum: |
- |
Fő részvényesek
Freefloat |
|
88,20% |
Capital Research and Management Company |
|
11,80% |